The Center for Biosimilars recaps the most-read articles of 2017.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the most-read biosimilars articles for the year of 2017.
Number 5: In January, The Center for Biosimilars® provided a look at the marketplace for prospective biosimilars referencing Humira, Enbrel, and Remicade.
Number 4: In December, the FDA approved Mylan and Biocon’s trastuzumab biosimilar, Ogivri, referenced on Herceptin.
Number 3: In January, Pfizer announced that CMS would reimburse for its biosimilar infliximab.
Number 2: In September, the FDA released a heavily redacted Form 483, noting observations that it made when inspecting Celltrion’s manufacturing facility earlier in 2017.
Number 1: In October, the FDA issued a Complete Response Letter for Mylan and Biocon’s pegfilgrastim biosimilar, referenced on Neulasta.
To read all of these articles and more, visit centerforbiosimilars.com.